Rilonacept — Membership Pricing

Other medications in Rheumatology

• Risankizumab
• Sarilumab
• Secukinumab
• Tocilizumab
• Tofacitinib
• Upadacitinib
• Voclosporin
• Abatacept

About Rilonacept

Rilonacept is a specialized medication used to treat certain rare and chronic inflammatory conditions, offering crucial relief for patients. For individuals facing the financial burden of such treatments, TheDrugClub offers pathways to potential savings. We aim to make essential medications like rilonacept more accessible, helping our members navigate high prescription costs and focus on their health journey.

Rilonacept, marketed under the brand name Arcalyst, is a vital medication for individuals suffering from specific inflammatory disorders. Primarily, it is approved to treat Cryopyrin-Associated Periodic Syndromes (CAPS), a group of rare, lifelong inflammatory conditions that includes Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). These conditions are characterized by recurrent episodes of fever, rash, joint pain, and other systemic inflammation. More recently, rilonacept has also been approved for the treatment of Recurrent Pericarditis (RP), a painful and often debilitating inflammatory disease affecting the sac around the heart.

At its core, rilonacept is an interleukin-1 (IL-1) blocker. IL-1 is

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Rilonacept is approved for (FDA label)

ARCALYST (rilonacept) is an interleukin-1 blocker indicated for: Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older ( 1.1 , 14.1 ) Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more ( 1.2 , 14.2 ) Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older ( 1.3 , 14.3 ) 1.1 Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome ARCALYST ® (rilonacept) is an interleukin-1 blocker indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and pediatric patients 12 years and older. 1.2 Deficiency of IL-1 Receptor Antagonist ARCALYST is indicated for the maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing at least 10 kg. 1.3 Recurrent Pericarditis ARCALYST is indicated for the treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older.

Source: Read the full FDA label on DailyMed. Label effective date: December 16, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Rilonacept (FDA label)

For injection: 220 mg of rilonacept as a white to off-white lyophilized powder for reconstitution in single-dose vials. For injection: 220 mg of lyophilized powder in a single-dose vial for reconstitution. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: ad965f38-dd22-4607-a673-2fb92f3b527a. SPL document ID: 11e22c54-9b9a-4f9f-8680-cb7327511a23. Label effective date: December 16, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Rilonacept (FDA label)

The following clinically significant adverse reactions are described elsewhere in the labeling. Serious Infections [see Warnings and Precautions (5.1) ] Risk of Malignancy [see Warnings and Precautions (5.2) ] Hypersensitivity Reactions [see Warnings and Precautions (5.3) ] Lipid Profile Changes [see Warnings and Precautions (5.4) ] The most common adverse reactions reported by patients with CAPS and RP treated with ARCALYST are injection-site reactions and upper respiratory tract infections. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Kiniksa at 1-833-KINIKSA (1-833-546-4572) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trial Experience Clinical trials are conducted under widely varying conditions and, as such, adverse reaction rates observed cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: ad965f38-dd22-4607-a673-2fb92f3b527a. SPL document ID: 11e22c54-9b9a-4f9f-8680-cb7327511a23. Label effective date: December 16, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Rilonacept (FDA label)

None. None. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: ad965f38-dd22-4607-a673-2fb92f3b527a. SPL document ID: 11e22c54-9b9a-4f9f-8680-cb7327511a23. Label effective date: December 16, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Rilonacept (FDA label)

Serious Infections : Serious, life-threatening infections have been reported in patients taking ARCALYST. Do not initiate treatment with ARCALYST in patients with active or chronic infections. Discontinue treatment if a patient develops a serious infection. ( 5.1 ) Hypersensitivity Reactions : If a hypersensitivity reaction occurs, discontinue administration of ARCALYST and initiate appropriate therapy. ( 5.3 ) Immunizations : Avoid live vaccines. Update recommended vaccinations prior to initiation of therapy per current guidelines. ( 5.5 ) 5.1 Serious Infections Interleukin-1 (IL-1) blockade may interfere with the immune response to infections. Treatment with another medication that works through inhibition of IL-1 has been associated with an increased risk of serious infections, and serious infections have been reported in patients taking ARCALYST [see Clinical Studies (14) ] . There was a greater incidence of infections in CAPS and RP patients on ARCALYST compared with placebo.

Source: FDA prescribing information (DailyMed). Set ID: ad965f38-dd22-4607-a673-2fb92f3b527a. SPL document ID: 11e22c54-9b9a-4f9f-8680-cb7327511a23. Label effective date: December 16, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Rilonacept (FDA label)

7.1 TNF-Blocking Agent and IL-1 Blocking Agent Specific drug interaction studies have not been conducted with ARCALYST. Concomitant administration of another drug that blocks IL-1 with a TNF-blocking agent in another patient population has been associated with an increased risk of serious infections and an increased risk of neutropenia. The concomitant administration of ARCALYST with TNF-blocking agents may also result in similar toxicities and is not recommended [see Warnings and Precautions (5.1) ] . The concomitant administration of ARCALYST with other drugs that block IL-1 has not been studied. Based upon the potential for pharmacologic interactions between rilonacept and a recombinant IL-1ra, concomitant administration of ARCALYST and other agents that block IL-1 or its receptors is not recommended. 7.2 Cytochrome P450 Substrates The formation of CYP450 enzymes is suppressed by increased levels of cytokines (e.g., IL-1) during chronic inflammation.

Source: FDA prescribing information (DailyMed). Set ID: ad965f38-dd22-4607-a673-2fb92f3b527a. SPL document ID: 11e22c54-9b9a-4f9f-8680-cb7327511a23. Label effective date: December 16, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.